A Phase II Trial of the Anti -PD-1 Monoclonal Antibody Pembrolizumab (MK-3475) + Lenalidomide + Dexamethasone as Post Autologous Transplant Consolidation in Patients With High-risk Multiple Myeloma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 11 Aug 2017
At a glance
- Drugs Dexamethasone (Primary) ; Lenalidomide (Primary) ; Pembrolizumab (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 08 Aug 2017 Status changed from recruiting to active, no longer recruiting.
- 10 Jun 2017 Biomarkers information updated
- 28 Dec 2016 Status changed from not yet recruiting to recruiting.